Erectile Dysfunction Treatment Market Size to Exceed USD 8.78 Bn by 2032

The Erectile Dysfunction Treatment Market, estimated at USD 5.26 Bn in 2025, is expected to exhibit a CAGR of 7.6% and reach USD 8.78 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Key market players are focusing on adopting inorganic growth strategies, such as acquisitions, which will drive the global erectile dysfunction treatment market growth. For instance, in March 2025, Lotus Pharmaceutical, a multinational pharmaceutical company, announced that its Board of Directors had approved to acquire the trademark, marketing authorization, and manufacturing know-how of Tadalafil 2.5mg, 5mg, 10mg, and 20mg under the brand name of Cialis in Taiwan for US$ 57.5 million from Eli Lilly and Company, a U.S. based pharmaceutical company. Tadalafil is indicated for the treatment of erectile dysfunction.

Global Erectile Dysfunction Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of things from one place to another.

Clinical trials and research efforts across various medical fields, including sexual health, were disrupted due to the pandemic. This could impact the development of new and improved treatments for erectile dysfunction. Thus, COVID 19 have a negative impact on the global erectile dysfuction treatment market.

Global Erectile Dysfunction Treatment Market: Key Developments

In September 2021, Oncotelic Therapeutics, Inc., an immuno-oncology company, executed a binding term sheet with Autotelic Inc., a company that specializes in therapeutic drug monitoring and development, to license AL-101 (intranasal apomorphine). Oncotelic Therapeutics, Inc intends to develop AL-101 via fast-to-market 505(b)2 regulatory pathway for Parkinson’s Disease (“PD”) and Erectile Dysfunction (“ED”), especially phosphodiesterase 5 (“PDE5”) non-responders.

In February 2021, Ferring Pharmaceuticals, a research-driven specialty biopharmaceutical group, divests its full rights for Testavan and Vitaros to Simple Pharma is a Pharmaceutical Manufacturing company. Vitaros (alprostadil cream) is the only topical cream that treats Erectile Dysfunction (ED). The treatment is a first line alternative for ED patients and especially patients who prefer local treatment or may not be candidates for oral PDE-5 inhibitors (sildenafil, tadalafil, vardenafil, and avanafil) due to medical constraints or concomitant medications. Vitaros is sold in more than 15 countries worldwide including through its licensing partners.

In May 2020, Neurotrope, Inc., a biopharmaceutical and diagnostics company, and Metuchen Pharmaceuticals, L.L.C., a privately-held biopharmaceutical company, announced that the two companies have entered into a definitive merger agreement under which Metuchen Pharmaceuticals, L.L.C. and Neurotrope, Inc. will merge in an all-stock transaction resulting in a newly formed holding company to be renamed Petros Pharmaceuticals, Inc. Petros Pharmaceuticals, Inc  is expected to become a Nasdaq traded company focused solely on men's health conditions. Petros Pharmaceuticals, Inc cornerstone product would be manufactured Metuchen's Stendra (avanafil) for Erectile Dysfunction ("ED").

Browse 32 Market Data Tables and 22 Figures spread through 180 Pages and in-depth TOC on “Global Erectile Dysfunction Treatment Market”- Forecast to 2030, Global Erectile Dysfunction Treatment Market, By Drugs ((Sildenafil (Viagra), Vardenafil (Levitra Staxyn), Tadalafil (Cialis), Avanafil (Stendra),  Udenafil (Zydena), and Others)), By Route of Administration (Oral Drugs, Injections, and Topical Application), By Distribution Channel (Hospital Pharmacies, Retail  Pharmacies, and Online  Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/erectile-dysfunction-market-200

Key Takeaways of the Global Erectile Dysfunction Treatment Market:

• The global erectile dysfunction treatment market is expected to exhibit a CAGR of 7.6% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global erectile dysfunction treatment market.
• Among drugs, the Sildenafil (Viagra) segment is expected to hold a dominant position in the global erectile dysfunction treatment market during the forecast period, and this is attributed to the increasing inorganic growth strategies by market players for erectile dysfunction treatment. For instance, in September 2020, Aspargo Laboratories, Inc., a privately-held, clinical stage, specialty pharmaceutical company, announced that it had entered into a definitive agreement with Farmalider, S.A., a private pharmaceutical company based in Madrid, Spain, to acquire the exclusive international patent rights related to a proprietary oral spray suspension formulation of sildenafil citrate (Sildenafil Oral Spray) for five million common shares. Aspargo Laboratories, Inc. acquired the exclusive U.S. patent rights covering Sildenafil Oral Spray from Farmalider, S.A. in January 2020.
• Among region, Asia Pacific is expected have the highest CAGR in the global erectile dysfunction treatment market, owing to market players focusing on inorganic growth strategies, such as acquisitions, to market products in the Asia Pacific region. For instance, in July 2021, Menarini Asia-Pacific Holdings Pte. Ltd., a part of the Menarini Group, the largest Italy-based biopharmaceutical company, announced the completion of its acquisition of Cialis in the People’s Republic of China from Eli Lilly and Company. Through the acquisition, Menarini Asia-Pacific Holdings Pte. Ltd., will take over the ownership of the brand and assume all sales, marketing, and distribution responsibilities. Cialis is a medication used to treat erectile dysfunction
• The major players operating in the global erectile dysfunction treatment market are Mangoceuticals, Inc, Futura Medical, CURE Pharmaceutical Holding Corp, Glenmark Pharmaceuticals Ltd, Mylan Pharmaceuticals Inc., Boston Scientific , Cipla Ltd , Pfizer Inc., Coloplast CORP, Eli Lily & Co, Gust Inc, Altera, Promedon, Dr. Reddys Laboratories Ltd, Bayer Pharma AG, and Reflexonic Llc.